



May 29, 2019

## **Launch of SIMPONI<sup>®</sup> Subcutaneous Injection 50 mg Autoinjector**

Mitsubishi Tanabe Pharma Corporation (MTPC) (Head Office: Osaka; President & Representative Director, CEO: Masayuki Mitsuka), announced today the launch of SIMPONI<sup>®</sup> Subcutaneous Injection 50 mg Autoinjector (generic name: golimumab (genetical recombination)), a human TNF-alpha monoclonal antibody, in Japan.

The SIMPONI<sup>®</sup> Subcutaneous Injection 50 mg Autoinjector is a disposable, spring-loaded product comprising an autoinjecting syringe filled with a drug solution whose composition is identical with that of SIMPONI<sup>®</sup> Subcutaneous Injection 50 mg Syringe available in Japan. Easy to grip and hold, only needing the push of a button to inject, this product has been specifically designed and developed to enhance the convenience of patients requiring at-home self-administered injections of SIMPONI<sup>®</sup>.

Please note that self-administration of SIMPONI<sup>®</sup> is possible only if patients' doctors justify such self-administration. Please also note that not all SIMPONI<sup>®</sup> Subcutaneous Injection 50 mg Syringes are replaced by SIMPONI<sup>®</sup> Subcutaneous Injection 50 mg Autoinjectors for at-home self-administration of injections. Healthcare workers need to discuss the proper use of each agent with patients and their families to choose the agent most suitable for the patients.

In April 2018, at-home self-administered injections of SIMPONI<sup>®</sup> for the treatment of rheumatoid arthritis was covered by insurance, but at present, at-home self-administered injections of SIMPONI<sup>®</sup> for the treatment of ulcerative colitis is not covered by insurance.

MTPC will continue to contribute to enhancing patients' quality of life by providing treatment options of SIMPONI<sup>®</sup> Subcutaneous Injection 50 mg Syringe and SIMPONI<sup>®</sup> Subcutaneous Injection 50 mg Autoinjector for patients and their families, enabling them to choose optimal treatment.

**Mitsubishi Tanabe Pharma Corporation**  
**Corporate Communications Department**

Media contacts: TEL:+81 6 6205 5119

Investor contacts: TEL:+81 6 6205 5110

About Strategic co-promotion agreement

Mitsubishi Tanabe Pharma has entered into a co-promotion agreement with Janssen for SIMPONI<sup>®</sup> in Japan. Under the terms of this agreement, Mitsubishi Tanabe Pharma has distributed SIMPONI<sup>®</sup> while Mitsubishi Tanabe Pharma and Janssen Pharmaceutical K.K. (Head Office: Chiyoda-ku, Tokyo; President: Chris Hourigan) have jointly promoted.